The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Open accessAbstract
Twenty-seven cases of inflammatory breast cancer were screened for the presence of the p53 protein by immunocytochemical methods using a monoclonal antibody directed against the p53 protein. Three groups were detected: 8 cases (30%) had high levels of p53 in the nucleus of the cancer cells; 9 cases (33%) had a complete lack of detectable staining; 10 cases (37%) showed a pattern of cytoplasmic staining with nuclear sparing. Nucleotide sequence analysis of p53 cDNAs derived from the samples with cytoplasmic staining revealed only wild-type p53 alleles in 6 out of 7 cases. An eighth case was determined to be wild type by a single-strand conformation polymorphism. In contrast, the samples containing nuclear p53 contained a variety of missense mutations and a nonsense mutation. The p53 cDNAs from 3 of the tumors that lacked detectable p53 staining were analyzed, and all 3 had wild-type nucleotide sequences. Interestingly, a case of normal lactating breast tissue also showed intense cytoplasmic staining for p53 with nuclear sparing. These data suggest that some breast cancers that contain the wild-type form of p53 protein may inactivate its tumor-suppressing activity by sequestering this protein in the cytoplasm, away from its site of action in the cell nucleus. The detection of cytoplasmic p53 in normal lactating breast tissue could suggest that this is the mechanism employed in specific physiological situations to permit transient cell proliferation. This observation could explain how some breast cancer tissues inactivate p53 function without mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“constitutive-cytoplasmic sequestration of p53 occurs in inflammatory breast cancer,11,12 neuroblastoma,13 retinoblastoma and some colon carcinomas14 and correlates with poor prognosis and resistance to therapy.”
From Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding (2010) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Self-citationOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Self-citationSuppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
p53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Cited by
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Self-citationTwenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
The mitochondrial pathways of apoptosis
Estaquier, J., Vallette, F., Vayssiere, J.-L., & Mignotte, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_7 · Cited by 637
“Nevertheless, cytoplasmic sequestration of p53 can also be associated to a physiological occurrence in some cell types such as in the mammary gland during lactation (Moll et al., 1992) or in embryonic stem cells (Aladjem et al., 1998) to permit transient proliferation.”
Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., & Levine, A. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.554 · Cited by 610
Self-citationStructure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 571
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
(1994) · PubMed · Cited by 509
Nuclear transport and cancer: from mechanism to intervention
Kau, T. R., Way, J. C., & Silver, P. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1274 · Cited by 468
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
Self-citationA comparison of the biological activities of wild‐type and mutant p53
Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 413
Self-citationThe p53 pathway in breast cancer
Gasco, M., Shami, S., & Crook, T. (2002) · Breast Cancer Research · doi:10.1186/bcr426 · Cited by 393
p53 is associated with cellular microtubules and is transported to the nucleus by dynein
Giannakakou, P., Sackett, D. L., Ward, Y., Webster, K. R., Blagosklonny, M. V., & Fojo, T. (2000) · Nature Cell Biology · doi:10.1038/35036335 · Cited by 373
Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., & Gu, W. (2003) · Cell · doi:10.1016/s0092-8674(02)01255-2 · Cited by 356
Transcription-independent p53 apoptosis: an alternative route to death
Speidel, D. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.10.002 · Cited by 356
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis
Wang, X., Simpson, E. R., & Brown, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0563 · Cited by 304
Mechanisms underlying hypoxia-induced neuronal apoptosis
Banasiak, K. J., Xia, Y., & Haddad, G. G. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00011-3 · Cited by 303
Cytoplasmic Sequestration of Wild-Type p53 Protein Impairs the G 1 Checkpoint after DNA Damage
Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., & Zambetti, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1126 · Cited by 277
Self-citationCytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’
Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E., Toriyama, S., Ikeda, R., Zhang, L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601490 · Cited by 275
Nucleocytoplasmic shuttling of signal transducers
Xu, L., & Massagué, J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1331 · Cited by 272
Fabian, C. J., Kimler, B. F., Zalles, C. M., Klemp, J. R., Kamel, S., Zeiger, S., & Mayo, M. S. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1217 · Cited by 272
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where?
Wadhwa, R., Taira, K., & Kaul, S. C. (2002) · Cell Stress & Chaperones · doi:10.1379/1466-1268(2002)007<0309:ahfcmm>2.0.co;2 · Cited by 262
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
(1994) · PubMed · Cited by 244
Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus
Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., & Pratt, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402223200 · Cited by 150
Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding
Marchenko, N. D., Hanel, W., Li, D., Becker, K., Reich, N., & Moll, U. M. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.173 · Cited by 123
Self-citationA p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Brekman, A., Singh, K. E., Polotskaia, A., Kundu, N., & Bargonetti, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2804 · Cited by 87
Nuclear translocation contributes to regulation of DNA excision repair activities
Knudsen, N. Ø., Andersen, S. D., Lützen, A., Nielsen, F. C., & Rasmussen, L. J. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.03.005 · Cited by 56
Pare, R., Shin, J., & Lee, C. S. (2016) · Histopathology · doi:10.1111/his.12948 · Cited by 37
Metadata
- Authors
- Moll, U. M., Riou, G., & Levine, A. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-08
- Volume
- 89
- Issue
- 15
- Pages
- 7262-7266
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1997646834
- Cited by
- 575
- References
- 32
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.